Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab
The identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of metastatic-colorectal-cancer (mCRC) patients. We previously reported the relevance of VEGF-A and some components of the renin–angiotensin-aldosterone system (R...
Main Authors: | M. José Ortiz-Morales, Marta Toledano-Fonseca, Rafael Mena-Osuna, M. Teresa Cano, Auxiliadora Gómez-España, Juan R. De la Haba-Rodríguez, Antonio Rodríguez-Ariza, Enrique Aranda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/13/3054 |
Similar Items
-
Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
by: Amy eBarone, et al.
Published: (2013-04-01) -
Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities
by: Aysegül Tura, et al.
Published: (2019-06-01) -
The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy
by: Katarzyna Masłowska, et al.
Published: (2021-03-01) -
Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued
by: Marie Mayenga, et al.
Published: (2023-07-01) -
The Effect of Intravitreal Bevacizumab on Apoptosis of Rat Retina Cells
by: Özcan Kayıkçıoğlu, et al.
Published: (2013-01-01)